Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
MENLO PARK, Calif., November 27, 2023--On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff’s belief that the Company is a "public shell," and that the continued listing of the Company’s securities is no longer warranted, and the Company’s non-compliance with certain board and committee composition listing
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. (“Morphogenesis”), for an all-stock transaction to advan
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annua
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ: CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline. The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade
Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and we
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. “I’m pleased
Company to host conference call and webcast at 5:00 p.m. ETMENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022. Managem
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01am ET on September